Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Helical van der Waals crystals with discretized Eshelby twist
Yin Liu, Jie Wang, Sujung Kim, Haoye Sun, Fuyi Yang, Zixuan Fang, Nobumichi Tamura, Ruopeng Zhang, Xiaohui Song, Jianguo Wen, Bo Xu, Michael Wang, Shuren Lin, Qin Yu, Kyle B. Tom, Yang Deng, J. Harvey Turner, Emory M. Chan, Dafei Jin, Robert O. Ritchie, Andrew M. Minor, D. C. Chrzan, Mary Scott, Jie Yao (2019). Helical van der Waals crystals with discretized Eshelby twist. Nature, 570(7761), pp. 358-362, DOI: 10.1038/s41586-019-1308-y.
Article375 days agoEfficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391)
Hervé Avet‐Loiseau, Rafaël Fonseca, David S. Siegel, Meletios A Dimopoulos, Ivan Špıčka, Tamás Masszi, Roman Hájek, Laura Rosiñol, Vesselina Goranova‐Marinova, Georgi Mihaylov, Vladimír Maisnar, María-Victoria Mateos, Michael Wang, Rubén Niesvizky, Albert Oriol, Andrzej Jakubowiak, Jiří Minařík, Antonio Palumbo, William Bensinger, Vishal Kukreti, Dina Ben‐Yehuda, Margaret Tonda, Mihaela Obreja, Philippe Moreau (2015). Efficacy and Safety of Carfilzomib, Lenalidomide, and Dexamethasone Vs Lenalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Aspire (NCT01080391). , 126(23), DOI: https://doi.org/10.1182/blood.v126.23.731.731.
Article36 days agoLenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function.
Donna Weber, Michael Wang, Christine Chen, Andrew R. Belch, Edward A. Stadtmauer, Ruben Niesvisky, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert Knight, Meletios A Dimopoulos (2006). Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function.. , 108(11), DOI: https://doi.org/10.1182/blood.v108.11.3547.3547.
Article36 days agoResponse and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
Meletios A Dimopoulos, Michael Wang, Vladimír Maisnar, Jiří Minařík, William Bensinger, María‐Victoria Mateos, Mihaela Obreja, Julie Blædel, Philippe Moreau (2018). Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. , 11(1), DOI: https://doi.org/10.1186/s13045-018-0583-7.
Article36 days agoCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
A. Keith Stewart, S. Vincent Rajkumar, Meletios A Dimopoulos, Tamás Masszi, Ivan Špıčka, Albert Oriol, Roman Hájek, Laura Rosiñol, David S. Siegel, Georgi Mihaylov, Vesselina Goranova‐Marinova, Péter Rajnics, Aleksandr Suvorov, Rubén Niesvizky, Andrzej Jakubowiak, Jesús F. San Miguel, Heinz Ludwig, Michael Wang, Vladimír Maisnar, Jiří Minařík, William Bensinger, María-Victoria Mateos, Dina Ben‐Yehuda, Vishal Kukreti, Naseem J. Zojwalla, Margaret Tonda, Xinqun Yang, Biao Xing, Philippe Moreau, Antonio Palumbo (2014). Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. , 372(2), DOI: https://doi.org/10.1056/nejmoa1411321.
Article36 days ago